Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer

被引：1

作者：

Abouharb, Sausan ^{[1
]}

Corn, Paul G. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, Houston, TX 77030 USA

来源：

CURRENT ONCOLOGY REPORTS | 2013年 / 15卷 / 03期

关键词：

Metastatic; Prostate cancer; Castration-resistant; Optimal sequencing; Individualized therapy; PHASE-II; INCREASED SURVIVAL; ANDROGEN ABLATION; CLINICAL-TRIAL; ABIRATERONE; IMMUNOTHERAPY; DOCETAXEL; CHEMOTHERAPY; BIOLOGY;

D O I：

10.1007/s11912-013-0311-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer is the most common cancer in men worldwide, accounting for approximately 242,000 new cases and 28,000 deaths annually in the USA. Although localized disease is often curable, advanced disease is generally not, especially when the cancer becomes castration-resistant and metastasizes to bone. Fortunately, advances in research have led to the recent approval of several novel therapies for the treatment of metastatic disease, and many other promising agents are in development. With this success arises the distinct challenge of optimizing both sequencing and the design of rational combinations with these agents. This review focuses on practical and experimental approaches to this challenge.

引用

页码：217 / 223

页数：7

共 37 条

[1]

Antonarakis ES, 2013, GU ASCO

[2]

Aparicio AM, 2008, ASCO ANN M

[3] Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer [J].

Armstrong, Andrew J. ;

Eisenberger, Mario A. ;

Halabi, Susan ;

Oudard, Stephane ;

Nanus, David M. ;

Petrylak, Daniel P. ;

Sartor, A. Oliver ;

Scher, Howard I. .

EUROPEAN UROLOGY, 2012, 61 (03) :549-559

[4] Bone-Targeting Radiopharmaceuticals Including Radium-223 [J].

Brady, Darren ;

Parker, Chris C. ;

O'Sullivan, Joe M. .

CANCER JOURNAL, 2013, 19 (01) :71-78

[5]

Buchanan G, 2001, CLIN CANCER RES, V7, P1273

[6] Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer [J].

Danila, Daniel C. ;

Morris, Michael J. ;

de Bono, Johann S. ;

Ryan, Charles J. ;

Denmeade, Samuel R. ;

Smith, Matthew R. ;

Taplin, Mary-Ellen ;

Bubley, Glenn J. ;

Kheoh, Thian ;

Haqq, Christopher ;

Molina, Arturo ;

Anand, Aseem ;

Koscuiszka, Michael ;

Larson, Steve M. ;

Schwartz, Lawrence H. ;

Fleisher, Martin ;

Scher, Howard I. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1496-1501

[7] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer [J].

Dayyani, Farshid ;

Gallick, Gary E. ;

Logothetis, Christopher J. ;

Corn, Paul G. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22) :1665-1675

[8] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[9]

Efstathiou E, 2011, ASCO ANN M

[10] Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer [J].

Fizazi, Karim ;

Beuzeboc, Philippe ;

Lumbroso, Jean ;

Haddad, Vincent ;

Massard, Christophe ;

Gross-Goupil, Marine ;

Di Palma, Mario ;

Escudier, Bernard ;

Theodore, Christine ;

Loriot, Yohann ;

Tournay, Elodie ;

Bouzy, Jeannine ;

Laplanche, Agnes .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) :2429-2435

← 1 2 3 4 →